Novartis is keeping JULIET in hiding, but the FDA takes a peek and hands over a ‘breakthrough’ title
There’s been considerable speculation of late about the data Novartis has collected from its JULIET study involving its closely-watched CAR-T drug. The pharma giant isn’t the best at communicating with the outside world and won’t say what it has seen so far or when exactly it will be put on display. But they have quietly given the FDA a peek, and regulators seem impressed.
In fact, the FDA has now handed over their breakthrough therapy designation for CTL019 as a new therapy for diffuse large B-cell lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
